Meningococcal groups a, b, c, w

On 1 register2 medicines2 companies

Where it is registered

Each register with its number of medicines and a few of them.

Every register, a page at a time. Strengths and packs are on each medicine’s page.

10 results

Medicine	Register	Strength	Form	Status	Holder
PenmenvyCombination	United States	25UG/0.5ML	Injection	Marketed	GlaxoSmithKline Biologicals
PenbrayaCombination	United States	5UG	Injection	Marketed	Pfizer Ireland Pharmaceuticals Unlimited Company
MenveoCombination	United States	0.5ML	Injection	Marketed	GlaxoSmithKline Biologicals
MenveoCombination	United States	0.5ML	Injection	Marketed	GlaxoSmithKline Biologicals
MenactraCombination	United States	48UG/.5ML	For Injection	Marketed	Sanofi Vaccines US Inc.
Menquadfi	United States	0.5ML	Injection	Marketed	Sanofi Vaccines US Inc.
MenQuadfiCombination	New Zealand		Inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial	Funded
NimenrixCombination	New Zealand		Inj 5 mcg of each meningococcal polysaccharide conjugated to a total of approximately 44 mcg of tetanus toxoid carrier per 0.5 ml vial	Funded
Penbraya	European Union			Withdrawn	Pfizer Europe MA EEIG
MenomuneCombination	United States	50UG/.5ML	For Injection	Withdrawn	Sanofi Vaccines US Inc.

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.